Back | Next |
home / stock / clls / clls message board
Subject | By | Source | When |
---|---|---|---|
Et like da (I) not da (o)(o) | MrPoppaGeorgeo | investorshub | 11/07/2015 1:57:10 AM |
vroom | ~Angel~ | investorshub | 11/07/2015 1:17:51 AM |
$CLLS has the V power (I) | MrPoppaGeorgeo | investorshub | 11/07/2015 12:48:05 AM |
Boooom $CLLS was just at $24 | MrPoppaGeorgeo | investorshub | 11/07/2015 12:46:46 AM |
http://www.reuters.com/article/2015/11/05/us-health-leukaemia-cellectis-idUSKCN0 | cantgetmyname | investorshub | 11/06/2015 3:09:31 PM |
Nice, this moves along with $JUNO..it's should be | MrPoppaGeorgeo | investorshub | 07/19/2015 5:34:49 PM |
I just go in this 37 it's a | Don'tDrinkTheKoolAid | investorshub | 07/18/2015 1:16:27 PM |
$CLLS news http://ih.advfn.com/p.php?pid=nmona&article=67231007 | MrPoppaGeorgeo | investorshub | 06/10/2015 11:00:52 PM |
Ready for a reload | MrPoppaGeorgeo | investorshub | 06/08/2015 10:44:05 PM |
$CLLS newsssss | MrPoppaGeorgeo | investorshub | 06/02/2015 9:08:44 PM |
and Poppa is nice, Liam ~ hehe | ~Angel~ | investorshub | 06/02/2015 7:10:27 PM |
Clls boom | MrPoppaGeorgeo | investorshub | 06/02/2015 2:22:18 PM |
39.60 reload opp | MrPoppaGeorgeo | investorshub | 06/02/2015 2:07:26 PM |
What a beast Liam.. :) | MrPoppaGeorgeo | investorshub | 05/29/2015 12:22:53 AM |
Very nice poppa!! | Liam859 | investorshub | 05/29/2015 12:21:37 AM |
You snooze you lose..$CLLS | MrPoppaGeorgeo | investorshub | 05/28/2015 11:54:42 PM |
On the way there , 69 \0/ ~ $CLLS | ~Angel~ | investorshub | 05/28/2015 10:09:35 PM |
$CLLS omg again!....lol | MrPoppaGeorgeo | investorshub | 05/28/2015 7:36:30 PM |
Go back to zzzz | MrPoppaGeorgeo | investorshub | 05/27/2015 8:03:20 PM |
Your call is good. Poot | ~Angel~ | investorshub | 05/27/2015 7:45:05 PM |
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...